Interim data from the Phase IIIb STARDUST study showed that 79% of patients with moderately to severely active Crohn’s disease (CD) achieved clinical response and 67% were in clinical remission.
News
Mumps at ‘decade high’ in England
Many of the cases in 2019 were seen in the so-called ‘Wakefield cohorts’ – young adults born in the late nineties and early 2000s who missed out on the MMR vaccine when they were children.
Verona publishes Phase II COPD results
Ensifentrine showed clinically and statistically significant improvements in lung function at all doses.
NICE recommends wireless device for overactive bladder
The device has potential to save the NHS around £6,200 per patient assuming a 15-year life span.
‘Lack of skills and distrust’ preventing patients from using internet
A “lack of skills and a distrust of health information online” are two of the biggest barriers keeping patients from using the internet.
Keytruda hits endpoints in triple-negative breast cancer
Earlier this week, NICE released a draft guidance rejecting Keytruda when used in combo with Pfizer’s Inlyta (axitinib) to treat advanced renal cell carcinoma.
Another mid-late stage Alzheimer’s flop, this time for Lilly
Earlier this month, Roche also announced a gantenerumab Alzheimer’s failure, and last year Biogen and Eisai stopped two global Phase III trials of aducanumab.
UK cancer patients able to ‘visualise’ treatment effects
The GenesisCare technology is part of a £20m investment.
New study reiterates benefits of stopping smoking at ‘any age’
More than nine out of every 10 lung cells in current smokers have up to 10,000 extra genetic changes compared to non-smokers.
Novartis’ investigational capmatinib granted FDA priority
If approved, it will become the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis.
NICE refuses Keytruda, Inlyta cancer combo
Despite evidence suggesting that the Keytruda combo would be welcomed by patients, NICE cites uncertainty around the long-term benefit.
Novartis unveils new London HQ
The company will also make the UK the global centre of a major new clinical trial to investigate the use of inclisiran in improving cardiovascular outcomes.
Final month of entries for the 2020 Clinical Researcher of the Year – The Americas
The 2020 competition will be closing for entry in just a months time on the 13th March.
UKRI launches ‘Nucleic Acid Therapy Accelerator’
Despite the recent approval of some high-profile nucleic acid therapy drugs, success has been modest, and there is still a “huge burden” of unmet medical need due to the vast number of diseases that are untreatable with traditional therapies.
KTE-X19 bags FDA Priority Review in mantle cell lymphoma
The EMA also recently validated a Marketing Authorisation Application for the drug.
